South Dakota · 2026 Regular Session · Bill

HB 1099: reschedule the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the Food and Drug Administration as a Schedule IV controlled substance.

Enacted Last action March 10, 2026: Signed by the Governor on 2026-03-10 H.J. 547

Plain-language summary

HB 1099 is a bill introduced in the South Dakota House on January 21, 2026. According to its official title, it concerns: reschedule the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the Food and Drug Administration as a Schedule IV controlled substance. Primary sponsor: Tom Pischke (Republican), Taylor Rehfeldt (Republican), Sydney Davis (Republican), Eric Emery (Democratic), Tim Goodwin (Republican), Mellissa Heermann (Republican), Scott Moore (Republican), Erik Muckey (Democratic), Brian Mulder (Republican), Carl Perry (Republican), Nicole Uhre-Balk (Democratic), Brandon Wipf (Republican), Kadyn Wittman (Democratic). Most recent recorded action (March 10, 2026): Signed by the Governor on 2026-03-10 H.J. 547.

Sponsors

Primary sponsors: Tom Pischke (Republican); Taylor Rehfeldt (Republican); Sydney Davis (Republican); Eric Emery (Democratic); and 9 more.